AIAsad Iqbal

Asad Iqbal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Asad Iqbal has a total of 85 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • To regress or not to regress? Outcomes of aneurysm sac behavior after Endovascular Aortic Aneurysm Repair: A systematic review and meta-analysis

    by Eren Çetinel, Asad Iqbal Khattak, Mostafa Labib, Andressa Frankowski Dagostin, Alexandra Bezborodova, Rafael Andrade Rego, Ghislain Irakoze Habiyambere, Dario Madera

  • Open Access

    Valve‐in‐Valve Transcatheter Mitral Valve Replacement Versus Redo Surgical Mitral Valve Replacement: Meta‐Analysis of Early and Late Outcomes

    by Michel Pompeu Sá, Gabriel Neves, Leo Consoli, Asad Iqbal, Leonardo Dexheimer, David Abraham Batista da Hora, Thiago Camarotti, Xander Jacquemyn, Federico Napoli, Antonio Polanco, et al.

    Background: Bioprosthetic mitral valve degeneration is traditionally treated with redo surgical mitral valve replacement (redo‐SMVR), but valve‐in‐valve transcatheter mitral valve replacement (ViV‐TMVR) offers a less invasive alternative. Methods: Systematic review and meta‐analysis of studies comparing ViV‐TMVR and redo‐SMVR. PubMed/MEDLINE, EMBASE, Web of Science, and Cochrane databases (inception to September 2025) were searched. Meta‐analyses were conducted with random‐effects models to assess patient‐relevant outcomes; Kaplan–Meier‐derived time‐to‐event data were pooled to assess late outcomes. Results: Thirteen observational studies met our eligibility criteria, including 15 941 patients (ViV‐TMVR: 5465; redo‐SMVR: 10476). In comparison with redo‐SMVR, ViV‐TMVR was associated with lower risk of in‐hospital mortality (risk ratio [RR], 0.72 [95% CI, 0.57–0.90]; P =0.004), stroke (RR, 0.49 [95% CI, 0.29–0.83]; P =0.008), bleeding (RR, 0.43 [95% CI, 0.20–0.94]; P =0.035), acute kidney injury (RR, 0.57 [95% CI, 0.42–0.77]; P P P P =0.256); however, the landmark analysis revealed that ViV‐TMVR was associated with lower risk of death in the initial 6 months (HR, 0.69 [95% CI, 0.58–0.83]; P P <0.001). Conclusions: In patients amenable to ViV‐TMVR, this procedure shows a lower initial risk of death and complications, but higher mortality after 6 months in comparison with redo‐SMVR. These findings highlight the importance of striking a balance between upfront surgical risk and estimated life expectancy when selecting interventions.


  • To regress or not to regress? Outcomes of aneurysm sac behavior after endovascular aortic aneurysm repair: A systematic review and meta-analysis

    by Eren Çetinel, Asad Iqbal Khattak, Mostafa Labib, Andressa Frankowski Dagostin, Alexandra Bezborodova, Rafael Andrade Rego, Ghislain Irakoze Habiyambere, Dario Madera


  • Open Access

    Burr hole craniostomy versus minicraniotomy for chronic subdural hematoma: an updated systematic review and meta-analysis

    by Muhammad Muneeb, Ayesha Naseem, Bilal Wazir Khan, Muhammad Waqar Shahid, Hamnah Sohail, Asad Iqbal, Shabina Bibi, Izhar Ul Haq, Muhammad Sufyan Darwish, Sarah Khan, et al.

    Background: Chronic subdural hematoma (CSHD) is a common neurological disorder, especially in older people and those on anticoagulant therapy, with incidences of 58 per 100,000 and 80 per 100,000 annually in those individuals over 65 and 75 years, respectively. It is caused by tearing of bridging veins after a minor head injury , presenting with signs and symptoms such as headache , gait disturbance , cognitive decline , hemiparesis , and even unconsciousness . The mortality rate for treated CSDH patients is relatively low, (2–5%) but can be significantly higher in older and medically frail patients, especially those with delayed diagnosis and recurrent hematomas. Objective: This systematic review and meta-analysis aimed to compare the safety, effectiveness, and perioperative outcomes of burr hole craniostomy [BHC] and minicraniotomy [MC] for the treatment of CSDH. Methods: PubMed, Embase, and Cochrane databases were systematically searched via relevant keywords from inception until July 12, 2025. A total of sixteen studies were included after the final screening. Outcomes were reported as the recurrence rate, reoperation rate, operation duration, mortality, postoperative complications, rate of good outcome, etc. Heterogeneity was assessed via I 2 (I > 50%=significant heterogeneity). Statistical calculations were performed via Review Manager 5.4.1 (The Cochrane Collaboration, Copenhagen, Denmark), with a p value of < 0.05 indicating statistical significance. Results: This meta-analysis included 15 observational studies and 1 RCT with a total of 4352 patients. Compared with MC, BHC was associated with a significantly lower reoperation rate (RR: 0.53, 95% 0.32 to 0.85; P = 0.009) and shorter operation duration (RR: -20.15, 95% CI: -28.99 to -11.31; P < 0.00001). However, there was no statistically significant difference between the groups in terms of the recurrence rate (RR: 0.69, 95% CI: 0.480.99, P = 0.05), mortality rate (RR:1.07, 95% CI: 0.741.54, P = 0.72), rate of good outcomes (RR:1.20, 95% CI: 0.991.46, P = 0.07), postoperative complications (RR:0.68, 95% CI: 0.441.06, P = 0.09), MGS score (RR: -0.02, 95% CI: -0.260.22, P = 0.87) or mark Walder score (RR: 1.06, 95% CI: 0.951.18, P = 0.29). Conclusion: CSHD, BHC, and MC offered similar clinical results. BHC, however, has benefits in terms of a shorter operative time and a lower reoperation rate.

  • Open Access

    Intensive versus standard blood pressure management after endovascular therapy in acute ischemic stroke: a systematic review and meta-analysis

    by Fatima Sajjad, Maria Qadri, Ayesha Arshad, Iqra Shahid, Asad Iqbal, Zoya Riaz, Umama Alam, Ammara Rehman, Gul Rukh Noreen, Muhammad Abdullah Ali, et al.

    Endovascular thrombectomy (EVT) has improved the therapy of acute ischemic stroke, patients still have functional impairments after reperfusion. This updated meta-analysis assesses whether intense blood pressure (BP) management following successful EVT enhances results and reduces problems associated with reperfusion. PubMed, Embase, and Cochrane databases were systematically searched using relevant keywords from inception until July 2025. A total of five studies were included after final screening. Outcomes were reported as excellent clinical outcomes, functional independence, all-cause mortality at 90 days, any intracranial hemorrhage within 24 h, etc. Interstudy heterogeneity was assessed using I 2 and X 2 statistics ( I 2 > 50% = significant heterogeneity). Statistical calculations used Review Manager 5.4.1, with a P -value of P = 0.03) and functional independence (mRS modified Rankin Scale 0–2) was both markedly enhanced by intensive BP control (RR = 0.82; 95% CI: 0.74–0.91; P = 0.0002). It did not, however, have a significant effect on all-cause death at 90 days, symptomatic or any cerebral bleeding, stroke recurrence, or excellent clinical outcomes (mRS 0–1). A significant correlation was seen between a greater incidence of hypotensive episodes and severe BP lowering (RR = 1.77; P < 0.00001). It also raises the risk of hypotension without reducing the danger of hemorrhage or death. Following EVT, intense BP control may enhance early neurological results and functional independence, but it also raises the risk of hypotension without reducing death or hemorrhage.

  • Sirolimus-Coated Versus Paclitaxel-Coated Balloons for Coronary Artery Disease: A Grade Assessed Systematic Review and Meta-Analysis

    by Fatima Sajjad, Asad Iqbal Khattak, Kanza Farhan, Ayesha Arshad, Abdullah Afridi, Muhammad Abdullah Ali, Iqra Shahid, Zeeshan Imtiaz, Hammad Naveed, Umama Alam, et al.

    Despite advances in percutaneous coronary procedures, in-stent restenosis remains a significant challenge. Although sirolimus- and paclitaxel-coated balloons are promising alternatives, their comparative safety and efficacy remain uncertain. PubMed, Embase, and Cochrane databases were searched using relevant keywords from inception until August 2025. A total of 11 studies (7 randomized controlled trials and 4 observational cohort studies) were included, comprising 3633 participants overall. The primary outcomes assessed were target lesion revascularization and target lesion failure. Meanwhile, the Secondary outcomes included stent thrombosis, all-cause mortality, myocardial infarction, major adverse cardiovascular events, survival, binary restenosis, and angiographic endpoints (acute gain, diameter stenosis, in-segment late lumen loss, in-lesion late lumen loss, and in-segment minimal lumen diameter). Interstudy heterogeneity was assessed using I ² and X ² statistics ( I ²>50% = significant heterogeneity). Interstudy heterogeneity was low for most outcomes, including all primary clinical endpoints, with moderate heterogeneity observed only for select angiographic measures (notably in-segment late lumen loss and diameter stenosis). Statistical analysis was conducted using R software and RStudio (version 4.4.2), with a P value of < 0.05 indicating statistical significance. This meta-analysis examined studies that compared paclitaxel-coated balloon (PCB) versus standard balloon [sirolimus-coated balloon (SCB)] angioplasty. Regarding primary outcomes, there were no notable variations in target lesion failure [risk ratio (RR), 1.08, 95% CI, 0.90–1.29, P = 0.36] or target lesion revascularization (RR, 1.16, 95% CI, 0.98–1.37, P = 0.08). With all aggregated estimates being nonsignificant, secondary outcomes such as stent thrombosis, all-cause mortality, myocardial infarction, major adverse cardiovascular events, and survival were similar between groups. Angiographic endpoints revealed no discernible variations in late lumen loss (in-lesion and in-segment), acute gain, or diameter stenosis. Nonetheless, the SCB group’s minimal lumen diameter was significantly smaller than that of the PCB group (MD, −0.08 mm, 95% CI, −0.14 to −0.01, P = 0.02). In treating coronary in-stent restenosis, SCB and PCBs show similar overall safety and effectiveness; lesion-specific angiographic variations indicate that customized selection may improve patient outcomes.


  • Efficacy and safety of intravenous tirofiban pre-operatively as an adjunct to endovascular thrombectomy in ischemic stroke: a grade-assessed systematic review and Meta-Analysis

    by Ayesha Altaf, Tahya Nazir, Abdullah Afridi, Kanza Farhan, Fatima Sajjad, Iqra Shahid, Fatima Imran, Aiman Gul, Umama Alam, Asad Iqbal, et al.

    Acute ischemic stroke (AIS) due to large vessel occlusion (LVO) is a significant cause of disability and mortality. While endovascular thrombectomy (EVT) is the standard treatment, microvascular reperfusion remains a challenge. Although there is mixed information about the safety and effectiveness of tirofiban, a glycoprotein IIb/IIIa inhibitor, it may improve perfusion when administered before EVT. Its effects on risks and functional outcomes, including symptomatic intracranial hemorrhage (sICH), are investigated in this meta-analysis. We systematically searched PubMed, Embase, and Cochrane from inception to July 2025 for randomized controlled trials (RCTs) and Cohorts comparing pre-EVT tirofiban with EVT alone in LVO stroke. Primary outcomes were 90-day functional independence and the ordinal shift in mRS. Secondary outcomes included mortality and symptomatic intracerebral hemorrhage. Six Studies (1,664 patients) were included. Tirofiban did not significantly improve 90-day functional independence (RR: 1.09, 95% CI: 0.88–1.36; p = 0.44; I² = 62%) or ordinal mRS (MD: 0.06, 95% CI: -0.15 to 0.27; p = 0.58; I² = 0%). Mortality was similar between groups (RR: 0.75, 95% CI: 0.54–1.06; p = 0.11; I² = 0%). sICH risk was also comparable (RR: 0.83, 95% CI: 0.46–1.51; p = 0.55; I² = 28%). Pre-procedural tirofiban did not significantly raise the risk of sICH, improve functional outcomes, or lower death in LVO stroke patients having EVT. Although additional research may improve patient selection, these results point to limited value for routine tirofiban administration before EVT. Keypoints Pre-EVT tirofiban does not significantly improve 90-day functional outcomes in AIS due to LVO. No significant benefit was observed in ordinal modified Rankin Scale scores. Mortality and risk of symptomatic intracranial hemorrhage were similar between tirofiban and control groups. Heterogeneity was moderate to low, and findings were consistent across study types. Future studies should explore optimal patient selection, dosing strategies, and timing to identify potential subgroups that may benefit from pre-EVT tirofiban. Graphical abstract

  • Open Access

    Efficacy and safety of indocyanine green fluorescence imaging in colorectal cancer: a systematic review and meta-analysis of randomized controlled trials

    by Abdullah Afridi, Ayesha Zulfiqar, Fatima Sajjad, Iqra Shahid, Hira Habib, Yasir Saleem, Zain Afridi, Asad Iqbal, Fazia Khattak, Farwa Nisa, et al.

    Background: The primary treatment for colorectal cancer, which is very prevalent, is surgery. Anastomotic leaking poses a significant risk following surgery. Intestinal perfusion can be objectively and instantly assessed with indocyanine green fluorescence imaging, which may lower leakage rates and enhance surgical results. Methods: PubMed, Embase, and Web of Science databases were systematically searched using relevant keywords from inception until 5th of March 2025. Eight studies were included after final screening. Outcomes were reported as overall anastomotic leakage, wound infection, paralytic ileus, mechanical ileus, and post-operative hospital stay. Interstudy heterogeneity was assessed using I 2 and X 2 statistics (I 2 > 50% = significant heterogeneity). Statistical calculations were performed using Review Manager 5.4.1 (The Cochrane Collaboration, Copenhagen, Denmark), with a p-value of < 0.05 indicating statistical significance. Results: This meta-analysis includes 4047 patients from eight investigations (2026 indocyanine green (ICG) group, 2021 non-ICG group). Overall anastomotic leak risk was considerably decreased with ICG use (risk ratio (RR) = 0.66; 95% CI: 0.54–0.81; p < 0.0001) and showed no heterogeneity (I 2 = 0%). There was no heterogeneity (I 2 = 0%) in the Grade A leakage occurrence, which was considerably lower in the ICG group (RR = 0.34; 95% CI: 0.16–0.72; p = 0.005). With little heterogeneity (I 2 = 8.6%), combined leakage grades also supported ICG use (RR = 0.54; 95% CI: 0.35–0.84; p = 0.006). ICG was associated with a substantial decrease in Clavien–Dindo Grade I complications (RR = 0.67; 95% CI: 0.49–0.92; p = 0.01) without heterogeneity (I 2 = 0%). Initial postoperative hospital stays, mechanical ileus, paralytic ileus, and abdominal bleeding did not differ significantly. Although there was no heterogeneity (I 2 = 0%), sensitivity analysis showed that the ICG group had a substantially longer postoperative stay (MD = 0.27; 95% CI 0.05–0.49; p = 0.02) and significantly fewer wound infections (RR = 0.17; 95% CI 0.04–0.76; p = 0.02). With noteworthy heterogeneity (I 2 = 70%), the ICG group’s operating time was significantly longer (MD = 8.26 min; 95% CI 0.52–16.00; p = 0.04). Conclusion: Although indocyanine green fluorescence imaging may marginally lengthen the recovery period and duration of operation, it dramatically lowers anastomotic leakage and wound infections following colorectal surgery, enhancing results.


  • Pharmacological Treatments for Menopausal Vasomotor Symptoms: A Systematic Review and Bayesian Network Meta-Analysis of Efficacy and Safety

    by Wellgner Fernandes Oliveira Amador, Cainã Araújo Saraiva, Mariano Gallo Ruelas, Ivo Queiroz, Asad Iqbal, Giovana de Souza Gaio, Juan Alejandro Pinilla Alarcón, Joao Roberto De Sa


  • Open Access

    Outcomes of transcatheter vs surgical aortic valve replacement in pre-existing chronic liver disease patients: A meta-analysis of observational studies

    by Aizaz Ali, Muhammad Abdullah Ali, Asad Iqbal Khattak, Fazia Khattak, Abdullah Afridi, Touba Azeem, Umme Salma Shabbar Banatwala, Umama Alam, Ayesha Khan, Urba Jalal, et al.